FATS expression is associated with cisplatin sensitivity in non small cell lung cancer.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Lung Cancer

• Publication date

  2012-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.lungcan.2011.11.009PMID 22137560
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Differentially expressed genes associated with cisplatin resistance in human ovarian adenocarcinoma cell line A2780.

  2011cited by this paper
• Hypoxia-induced cisplatin resistance is reversible and growth rate independent in lung cancer cells.

  2011cited by this paper
• Adenylate Kinase 3 Sensitizes Cells to Cigarette Smoke Condensate Vapor Induced Cisplatin Resistance

  2011cited by this paper
• The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells

  2011cited by this paper
• Genes potentially associated with Cisplatin resistance of lung cancer cells

  2011cited by this paper
• An HDAC1-binding domain within FATS bridges p21 turnover to radiation-induced tumorigenesis

  2010cited by this paper
• FATS is a transcriptional target of p53 and associated with antitumor activity

  2010cited by this paper
• Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer.

  2010influential reference
• Fhit loss in lung preneoplasia: relation to DNA damage response checkpoint activation.

  2010cited by this paper
• Pathology and biology associated with the fragile FHIT gene and gene product

  2010cited by this paper
• Fragile histidine triad protein, WW domain‐containing oxidoreductase protein Wwox, and activator protein 2γ expression levels correlate with basal phenotype in breast cancer

  2009cited by this paper
• Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancer.

  2008cited by this paper
• Fhit tumor suppressor: guardian of the preneoplastic genome.

  2008cited by this paper
• Cisplatin nephrotoxicity: mechanisms and renoprotective strategies.

  2008cited by this paper
• Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.

  2008cited by this paper
• Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care

  2008cited by this paper
• Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer.

  2007cited by this paper
• A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship.

  2007cited by this paper
• Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis.

  2007cited by this paper
• Fhit modulates the DNA damage checkpoint response.

  2006cited by this paper
• DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

  2006cited by this paper
• Predicting the outcome of chemotherapy for lung cancer.

  2006cited by this paper
• Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients.

  2006cited by this paper
• The role of adjuvant chemotherapy for non-small cell lung cancer.

  2005cited by this paper
• Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.

  2005cited by this paper
• Cancer Statistics, 2005

  2005cited by this paper
• Cytotoxic Chemotherapy in Advanced Non-Small Cell Lung Cancer

  2004cited by this paper
• Decreased FHIT protein expression correlates with a worse prognosis in patients with diffuse large B-cell lymphoma.

  2004cited by this paper
• Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

  2004cited by this paper
• American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

  2004cited by this paper
• Phosphorylation/Cytoplasmic Localization of p21Cip1/WAF1 Is Associated with HER2/neu Overexpression and Provides a Novel Combination Predictor for Poor Prognosis in Breast Cancer Patients

  2004cited by this paper
• Differential effects of cell cycle regulatory protein p21(WAF1/Cip1) on apoptosis and sensitivity to cancer chemotherapy.

  2003cited by this paper
• Abnormal Fhit expression is an independent poor prognostic factor for cervical cancer

  2003cited by this paper
• Cytoplasmic p21WAF1/CIP1 expression is correlated with HER-2/ neu in breast cancer and is an independent predictor of prognosis

  2003cited by this paper
• Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis.

  2001cited by this paper
• WWOX, the FRA16D gene, behaves as a suppressor of tumor growth.

  2001cited by this paper
• Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells

  2001cited by this paper
• The hereditary renal cell carcinoma 3;8 translocation fuses FHIT to a patched-related gene, TRC8.

  1998cited by this paper
• Requirement for p53 and p21 to sustain G2 arrest after DNA damage.

  1998cited by this paper
• Frequent deletions of FHIT and FRA3B in Barrett's metaplasia and esophageal adenocarcinomas

  1997cited by this paper
• Revisions in the International System for Staging Lung Cancer.

  1997cited by this paper
• Prognostic value of p21(WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up.

  1996cited by this paper
• Radiation-induced cell cycle arrest compromised by p21 deficiency

  1995cited by this paper
• Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.

  1986cited by this paper

• FATS alleviates ulcerative colitis by inhibiting M1 macrophage polarization and aerobic glycolysis through promoting the ubiquitination-mediated degradation of HIF-1α.

  2025cites this paper
• Role of fragile sites FATS and FMR1 in tumor progression and their potential clinical significance

  2025cites this paper
• Blockade of neutral sphingomyelinase 2 exerts antitumor effect on metastatic castration resistant prostate cancer cells and promotes tumor regression when combined with Enzalutamide.

  2024cites this paper
• FATS inhibits the Wnt pathway and induces apoptosis through degradation of MYH9 and enhances sensitivity to paclitaxel in breast cancer

  2024cites this paper
• Association study between C10orf90 gene polymorphisms and colorectal cancer

  2023cites this paper
• Loss of fragile site-associated tumor suppressor promotes antitumor immunity via macrophage polarization

  2021cites this paper
• The T-Cell-Inflammation Status Can Predict Outcomes of Adjuvant Chemotherapy in Patients with Gastric Cancer

  2020cites this paper
• FATS regulates polyamine biosynthesis by promoting ODC degradation in an ERβ-dependent manner in non-small-cell lung cancer

  2020cites this paper
• Functional CRISPR and shRNA Screens Identify Involvement of Mitochondrial Electron Transport in the Activation of Evofosfamide

  2019cites this paper
• miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway

  2018cites this paper
• Regulation of cytotoxicity and apoptosis-associated pathways contributes to the enhancement of efficacy of cisplatin by baicalein adjuvant in human A549 lung cancer cells.

  2017cites this paper
• The value of FATS expression in predicting sensitivity to radiotherapy in breast cancer

  2017cites this paper
• A functional genetic variant in fragile-site gene FATS modulates the risk of breast cancer in triparous women

  2015cites this paper
• FATS is an E2-independent ubiquitin ligase that stabilizes p53 and promotes its activation in response to DNA damage

  2014cites this paper
• Common Fragile Sites: Genomic Hotspots of DNA Damage and Carcinogenesis

  2012cites this paper